ABACAVIR, LAMIVUDINE AND ZIDOVUDINE

Lupin Pharmaceuticals, Inc.🇺🇸 United States

FDA Page

Effective Date: Oct 31, 2023
Approval ID: f5f7c0d9-a247-4308-8269-32accc490ea6
Products: 1 registered
Version: 16

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use ABACAVIR, LAMIVUDINE AND ZIDOVUDINE TABLETS safely and effectively. See full prescribing information for ABACAVIR, LAMIVUDINE AND ZIDOVUDINE TABLETS. ABACAVIR, LAMIVUDINE and ZIDOVUDINE tablets, for oral useInitial U.S. Approval: 2000

Quick Stats

Total Products1

Labelers2

Label Sections18

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.